`
`2007 > FDA Approves Tykerb for Advanced Breast Cancer Patients
`
`Archived Content
`The content on this page is provided for reference purposes only. This content has not
`been altered or updated since it was archived.
`
`Search Archive
`
`Home3 News & Events4 Newsroom5 Press Announcements6 20077
`News & Events
`FDA NEWS RELEASE
`FOR IMMEDIATE RELEASE
`P0744
`March 13, 2007
`
`Media Inquiries:
`Susan Cruzan, 3018276242
`Consumer Inquiries:
`888INFOFDA
`
`FDA Approves Tykerb for Advanced Breast Cancer Patients
`The Food and Drug Administration (FDA) today approved Tykerb (lapatinib), a new targeted anticancer
`treatment, to be used in combination with capectabine (Xeloda), another cancer drug, for patients with
`advanced, metastatic breast cancer that is HER2 positive (tumors that exhibit HER2 protein). The
`combination treatment is indicated for women who have received prior therapy with other cancer drugs,
`including an anthracycline, a taxane, and trastuzumab (Herceptin). According to the American Cancer
`Society, about 180,000 new cases of breast cancer are diagnosed each year. Approximately 8,000 to
`10,000 women die from metastatic HER2 positive breast cancer each year.
`Tykerb, a new molecular entity (NME), is a kinase inhibitor working through multiple pathways (targets) to
`deprive tumor cells of signals needed to grow. Unlike, for example, trastuzumab — a monoclonal antibody,
`which is a large protein molecule that targets the part of the HER2 protein on the outside of the cell —
`Tykerb is a small molecule that enters the cell and blocks the function of this and other proteins. Because
`of this difference in mechanism of action, Tykerb works in some HER2 positive breast cancers that have
`been treated with trastuzumab and are no longer benefiting.
`"Today's approval is a step forward in making new treatments available for patients who have progression of
`their breast cancer after treatment with some of the most effective breast cancer therapies available," said
`Steven Galson, MD, M.P.H., Director of FDA's Center for Drug Evaluation and Research. "New targeted
`therapies such as Tykerb are helping expand options for patients."
`The approval of Tykerb was based on a randomized clinical trial in about 400 women with advanced or
`metastatic breast cancer that was also HER2 positive. In the trial, half the patients received Tykerb with
`capecitabine and half received capecitabine alone. Compared to patients receiving capecitabine alone, the
`group of patients receiving Tykerb with capecitabine had a statistically significant improvement in the time
`to tumor progression. In addition, the tumor response rate was higher in the group of patients receiving
`Tykerb with capecitabine (24 percent vs. 14 percent). The survival data are not yet mature.
`The most commonly reported Tykerbrelated side effects included diarrhea, nausea, vomiting, rash and
`handfoot syndrome which may include numbness, tingling, redness, swelling and discomfort of hands and
`feet. Generally reversible decreases in heart function (that can lead to shortness of breath) have also been
`reported in a small percentage of patients. Patients should talk to their doctor about potential side effects,
`potential drug interactions, and other medical conditions including heart and liver problems. Tykerb is
`available in tablets of 250 mg. An undivided dose of 1,250 mg should be taken orally once daily for 21 days
`and in combination with capecitabine on days 114 of a 21 day cycle.
`Tykerb will be distributed by GlaxoSmithKline, of Research Triangle Park, North Carolina.
`
`#
`
`RSS Feed for FDA News Releases10 [what is RSS?11]
`
`http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108866.htm
`
`1/2
`
`IMMUNOGEN 2055, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`
`
`2007 > FDA Approves Tykerb for Advanced Breast Cancer Patients
`
`12/18/2014
`Page Last Updated: 04/10/2013
`Note: If you need help accessing information in different file formats, see Instructions for Downloading
`Viewers and Players.
`Accessibility Contact FDA Careers FDA Basics FOIA No Fear Act Site Map Transparency Website
`Policies
`
`U.S. Food and Drug Administration
`10903 New Hampshire Avenue
`Silver Spring, MD 20993
`Ph. 1888INFOFDA (18884636332)
`Email FDA
`
`
`
`
`
`
`
`
`
`For Government For Press
`Combination Products Advisory Committees Science & Research Regulatory Information Safety
`Emergency Preparedness International Programs News & Events Training and Continuing Education
`Inspections/Compliance State & Local Officials Consumers Industry Health Professionals FDA Archive
`
`Links on this page:
`1. http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain
`2. http://www.addthis.com/bookmark.php
`3. /default.htm
`4. /NewsEvents/default.htm
`5. /NewsEvents/Newsroom/default.htm
`6. /NewsEvents/Newsroom/PressAnnouncements/default.htm
`7. /NewsEvents/Newsroom/PressAnnouncements/2007/default.htm
`8. /NewsEvents/Newsroom/default.htm
`9. /NewsEvents/Newsroom/PressAnnouncements/default.htm
`10. /AboutFDA/ContactFDA/StayInformed/RSSFeeds/PressReleases/rss.xml
`11. ssLINK/ucm144575.htm
`
`http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108866.htm
`
`2/2
`
`IMMUNOGEN 2055, pg. 2
`Phigenix v. Immunogen
`IPR2014-00676
`
`